Earnings ·
Kyverna Therapeutics reported second quarter 2026 financial results on August 11, 2026
KYTXKyverna Therapeutics, Inc.
Kyverna Therapeutics reported second quarter 2026 financial results on August 11, 2026. The company posted a net loss of $38.3 million, or $0.63 per share, with research and development expenses at $24.8 million and general and administrative expenses at $14.8 million. Cash, cash equivalents, and marketable securities totaled $199.4 million as of June 30, 2026, providing an operating runway into 2028. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for miv-cel in non-active secondary progressive multiple sclerosis based on clinical data from Stanford University and UCSF. Kyverna initiated a rolling Biologic License Application submission for stiff person syndrome and expects to complete enrollment in its Phase 3 generalized myasthenia gravis trial by mid-2027. The company also appointed Greg Martini as CFO, Nadia Dac as Chief Commercial Officer, and Ritesh Srivastava as Chief Legal and Compliance Officer during the quarter. Kyverna Therapeutics is a late-stage clinical immunology company pioneering CAR T-cell therapies for neurologic autoimmune diseases.